image of a doctors reviewing paperwork.

This research study is evaluating an investigational medical food, known as enterade®, to determine if it might reduce quality-of-life-limiting diarrhea due to carcinoid or non-carcinoid neuroendocrine tumors. Patients who enroll in this study will be asked to participate for a total of 12 weeks. After an initial 4-week observation period, patients take enterade® (8 oz.) two times a day (BID), 30 minutes before meals on an empty stomach for a period of 4 weeks. There will be a total of 4 follow-up study visits over the period of the study.

Study Criteria

To participate in this study, patients must:

  • Be 18 years or older
  • Have a diagnosis of NET
  • Have 4 or more bowel movements per day on standard anti-diarrheal regimen
  • Have no history of inflammatory bowel disease, IBS, Celiac, etc.
  • Have no known allergy to Stevia
  • Have no known diagnosis or history of Clostridium difficil infection, also known as C. diff
  • Not have consumed enterade® within the past 45 days

Women who are pregnant or breastfeeding are not eligible to participate. Other criteria for eligibility apply. Study participants receive study-related medical exams and study product at no cost. Patients who complete the study will receive a free 1-month supply of enterade®.

image of the enterade® Drinks

Study Beverage

Enterade® is a plant-based medical food delivered in the form of a beverage. Patients will receive orange and/or vanilla flavors of this study beverage. This medical food has been previously studied in other clinical trials, during which there were no known side effects. This is the first clinical trial that is evaluating the ability of enterade® to reduce bowel movement frequency in carcinoid and non-carcinoid NET patients. Together, we can work towards an improved quality of life for patients with neuroendocrine tumors.